Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | DUT | P33316 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17493276 | 0.96 | MAPT (0.50) | MAPTRAB9ASMN1; SMN2DUTCYP1A2 | |
| SCHEMBL17743343 | 0.94 | TDP1 (0.49) | MAPTRAB9ASMN1; SMN2DUTCYP1A2 | |
| SCHEMBL12903756 | 0.91 | HPGD (0.51) | MAPTRAB9ASMN1; SMN2DUTKMT2A | |
| SCHEMBL18419336 | 0.86 | DUT (0.47) | MAPTRAB9ASMN1; SMN2DUTKMT2A | |
| SCHEMBL2205221 | 0.84 | RAB9A (0.60) | MAPTRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL15894550 | 0.83 | HEXA (0.47) | RAB9A | |
| SCHEMBL2205040 | 0.83 | RAB9A (0.59) | MAPTRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL754531 | 0.81 | KMT2A (0.48) | MEN1KMT2A | |
| SCHEMBL4851745 | 0.81 | RECQL (0.55) | MAPTDUTCYP1A2MEN1KMT2A | |
| SCHEMBL12767494 | 0.81 | GAA (0.51) | MAPTDUTCYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604051-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2013-12-10 | — | — | US | disclosed |
| US-8470763-B2 | Alpha-amino-N-substituted amides, pharmaceutical composition containing them and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2013-06-25 | — | — | US | disclosed |
| US-8470763-B2 | Alpha-amino-N-substituted amides, pharmaceutical composition containing them and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2013-06-25 | — | — | US | disclosed |
| US-20130150573-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2013-06-13 | — | — | US | disclosed |
| US-8394822-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA, S.A. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-20120329774-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2012-12-27 | — | — | US | disclosed |
| US-8283359-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2012-10-09 | — | — | US | disclosed |
| US-20110021624-A1 | Alpha-Amino-N-Substituted Amides, Pharmaceutical Composition Containing Them and Uses Thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2011-01-27 | — | — | US | disclosed |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | US | disclosed |
| EP-1981892-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB Pharma, S.A. (BE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007088345-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021624-A1 | Alpha-Amino-N-Substituted Amides, Pharmaceutical Composition Containing Them and Uses Thereof | AADAT, ASNS, AANAT | MAPT 1742/4885RAB9A 1170/4885SMN1; SMN2 2565/4885 |
| US-20120329774-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | MAPT 2869/4885RAB9A 1435/4885SMN1; SMN2 3067/4885 |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | MAPT 2869/4885RAB9A 1435/4885SMN1; SMN2 3067/4885 |
| US-20130150573-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP2K2, MAPK1, MAP3K6 | MAPT 3183/4885RAB9A 1611/4885SMN1; SMN2 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.